Capital International Ltd. CA purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,217 shares of the life sciences company's stock, valued at approximately $6,042,000.
A number of other large investors have also recently added to or reduced their stakes in the stock. WCM Investment Management LLC increased its holdings in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares during the period. Norges Bank acquired a new position in Illumina in the fourth quarter worth $228,714,000. Bessemer Group Inc. increased its stake in Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after purchasing an additional 1,344,038 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Illumina by 245.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company's stock worth $158,011,000 after purchasing an additional 840,423 shares during the period. 89.42% of the stock is currently owned by institutional investors.
Illumina Price Performance
Shares of Illumina stock traded down $2.32 on Friday, hitting $71.21. The company had a trading volume of 2,639,652 shares, compared to its average volume of 2,274,954. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a market cap of $11.27 billion, a PE ratio of -9.27, a PEG ratio of 1.60 and a beta of 1.38. The business has a 50-day simple moving average of $84.61 and a 200-day simple moving average of $120.16. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
ILMN has been the subject of several research reports. Citigroup decreased their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Barclays decreased their target price on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday, April 10th. Stephens reiterated an "overweight" rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Guggenheim cut their price target on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada lowered their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.70.
Get Our Latest Report on ILMN
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
